201 related articles for article (PubMed ID: 30402885)
1. Pathological complete response after neoadjuvant pembrolizumab and radiation.
Mynard JN; Conry RM; De Los Santos J; Gordetsky JB; Contreras CM
Clin Exp Dermatol; 2019 Jul; 44(5):570-573. PubMed ID: 30402885
[No Abstract] [Full Text] [Related]
2. Pembrolizumab (Keytruda°) and metastatic or inoperable melanoma.
Prescrire Int; 2017 May; 26(182):118-119. PubMed ID: 30730667
[No Abstract] [Full Text] [Related]
3. Major response to pembrolizumab in two patients with locally advanced cutaneous squamous cell carcinoma.
Degache E; Crochet J; Simon N; Tardieu M; Trabelsi S; Moncourier M; Templier I; Foroni L; Lemoigne A; Pinel N; Gil H; Bouillet L; Leccia MT; Charles J
J Eur Acad Dermatol Venereol; 2018 Jul; 32(7):e257-e258. PubMed ID: 28557105
[No Abstract] [Full Text] [Related]
4. Complete Pathologic Response When Adding Pembrolizumab to Neoadjuvant Chemotherapy in Stage IIIA Non-Small-Cell Lung Cancer.
Hill A; Gong J; Wilczynski S; Mirza R; Erhunmwunsee L; Salgia R
J Oncol Pract; 2018 Sep; 14(9):569-571. PubMed ID: 30044685
[No Abstract] [Full Text] [Related]
5. Killing two birds with one stone: response to pembrolizumab in a patient with metastatic melanoma and B-cell chronic lymphocytic leukaemia.
Arenbergerova M; Fialova A; Arenberger P; Gkalpakiotis S; Jirasek T; Srp A; Novotna A; Frankova H
J Eur Acad Dermatol Venereol; 2018 Feb; 32(2):e72-e74. PubMed ID: 28833722
[No Abstract] [Full Text] [Related]
6. Definite regression of cutaneous melanoma metastases upon addition of topical contact sensitizer diphencyprone to immune checkpoint inhibitor treatment.
Gulati N; Carvajal RD; Postow MA; Wolchok JD; Krueger JG
Exp Dermatol; 2016 Jul; 25(7):553-4. PubMed ID: 27061281
[No Abstract] [Full Text] [Related]
7. Coincident Metastatic Melanoma and Merkel Cell Carcinoma with Complete Remission on Treatment with Pembrolizumab.
Thiem A; Kneitz H; Schummer P; Herz S; Schrama D; Houben R; Goebeler M; Schilling B; Gesierich A
Acta Derm Venereol; 2017 Nov; 97(10):1252-1254. PubMed ID: 28761962
[No Abstract] [Full Text] [Related]
8. Persistence of superficial basal cell carcinoma during pembrolizumab treatment for metastatic melanoma.
Russo I; Filoni A; Alaibac M
Eur J Dermatol; 2021 Feb; 31(1):99-100. PubMed ID: 33586650
[No Abstract] [Full Text] [Related]
9. A single dose of neoadjuvant PD-1 blockade predicts clinical outcomes in resectable melanoma.
Huang AC; Orlowski RJ; Xu X; Mick R; George SM; Yan PK; Manne S; Kraya AA; Wubbenhorst B; Dorfman L; D'Andrea K; Wenz BM; Liu S; Chilukuri L; Kozlov A; Carberry M; Giles L; Kier MW; Quagliarello F; McGettigan S; Kreider K; Annamalai L; Zhao Q; Mogg R; Xu W; Blumenschein WM; Yearley JH; Linette GP; Amaravadi RK; Schuchter LM; Herati RS; Bengsch B; Nathanson KL; Farwell MD; Karakousis GC; Wherry EJ; Mitchell TC
Nat Med; 2019 Mar; 25(3):454-461. PubMed ID: 30804515
[TBL] [Abstract][Full Text] [Related]
10. Complete response to pembrolizumab after initial progress in a patient with metastatic uveal melanoma.
Stauner CT; Drexler K; Berneburg M; Haferkamp S
J Dtsch Dermatol Ges; 2018 Nov; 16(11):1376-1378. PubMed ID: 30299577
[No Abstract] [Full Text] [Related]
11. Antiphospholipid Syndrome Following Pembrolizumab Treatment of Stage IIIB Unresectable Melanoma.
Sanchez A; Montaudie H; Bory P; Belgodere X; Passeron T; Lacour JP; Picard A
JAMA Dermatol; 2018 Nov; 154(11):1354-1356. PubMed ID: 30326507
[No Abstract] [Full Text] [Related]
12. Multiple "halo nevi" occurring during pembrolizumab treatment for metastatic melanoma.
Nicolétis-Lombart I; Kervarrec T; Zaragoza J; Machet MC; Samimi M
Int J Dermatol; 2019 Jun; 58(6):739-741. PubMed ID: 30229873
[No Abstract] [Full Text] [Related]
13. Pearls & Oy-sters: Pembrolizumab-induced myasthenia gravis.
Algaeed M; Mukharesh L; Heinzelmann M; Kaminski HJ
Neurology; 2018 Oct; 91(14):e1365-e1367. PubMed ID: 30275130
[No Abstract] [Full Text] [Related]
14. Complete Tumor Response to Pembrolizumab and Allograft Preservation in Renal Allograft Recipient on Immunosuppressive Therapy.
Sadaat M; Jang S
J Oncol Pract; 2018 Mar; 14(3):198-199. PubMed ID: 29257718
[No Abstract] [Full Text] [Related]
15. Complete response with neoadjuvant avelumab in Merkel cell carcinoma - A case report.
Abdallah N; Nagasaka M; Chowdhury T; Raval K; Hotaling J; Sukari A
Oral Oncol; 2019 Dec; 99():104350. PubMed ID: 31277904
[TBL] [Abstract][Full Text] [Related]
16. Surgical Considerations and Systemic Therapy of Melanoma.
Gamboa AC; Lowe M; Yushak ML; Delman KA
Surg Clin North Am; 2020 Feb; 100(1):141-159. PubMed ID: 31753109
[TBL] [Abstract][Full Text] [Related]
17. Is it metastatic melanoma or is it sarcoidosis? Non-caseating granulomas due to pembrolizumab.
Chahin M; Stack A; Siddiqi A; Shaikh M
BMJ Case Rep; 2020 Dec; 13(12):. PubMed ID: 33371005
[No Abstract] [Full Text] [Related]
18. Pembrolizumab for Recurrent Conjunctival Melanoma.
Kini A; Fu R; Compton C; Miller DM; Ramasubramanian A
JAMA Ophthalmol; 2017 Aug; 135(8):891-892. PubMed ID: 28715523
[No Abstract] [Full Text] [Related]
19. Isolated immune-related pancreatic exocrine insufficiency associated with pembrolizumab therapy.
Prasanna T; McNeil CM; Nielsen T; Parkin D
Immunotherapy; 2018 Mar; 10(3):171-175. PubMed ID: 29370723
[TBL] [Abstract][Full Text] [Related]
20. Massive Periocular Squamous Cell Carcinoma With Response to Pembrolizumab (Keytruda).
Conger JR; Grob SR; Tao J
Ophthalmic Plast Reconstr Surg; 2019; 35(5):e127. PubMed ID: 30925541
[No Abstract] [Full Text] [Related]
[Next] [New Search]